Pharmacological compounds, such as the thiazolidinediones (TDZ), that target PPARγ activity have thus been exploited as insulin sensitizers, and are now widely used for the treatment of insulin resistance in T2DM patients. Here, INS is linked to type 2 diabetes mellitus.